Adult Subjects With Uncontrolled Type 2 Diabetes

Objectives

• To assess the safety, tolerability and initial anti-diabetic activity of MLR-1023 in subjects with uncontrolled mild to moderate type 2 diabetes mellitus
• To evaluate the pharmacokinetics of MLR-1023 and the major metabolite, MLR-1023-M1 following 28 days of repeat dosing

Design and Outcomes

The study is a randomized, double blind, placebo-controlled, parallel group study of MLR-1023 in adult subjects with uncontrolled type 2 diabetes mellitus who are on diet and exercise therapy.

A subset of subjects per dose group will have additional samples analyzed to measure signs of MLR-1023.

Inclusion criteria

• Diagnosed with uncontrolled T2DM who have received diet and exercise therapy for at least 3 months prior to screening, aged ≥ 18 - ≤ 75 years
• Females must be post-menopausal, unable to conceive, or test negative for pregnancy via blood test and use barrier contraception
• BMI ranging from ≥ 20 to ≤ 40 kg/m2
• Fasting plasma glucose values of up to 240 mg/dL at screening, after wash-out (visit 2) and after placebo run-in (visit 3)
• (i) naïve or (ii) currently using and discontinued metformin or (iii) no prior exposure to anti-diabetic agents other than metformin ≥ 6 months prior to screening

Exclusion criteria

• History of Type 1 diabetes
• History of more than 1 episode of severe hypoglycemia within 6 months prior to screening, or a current diagnosis of hypoglycemia unawareness.
• Hospitalizations or Emergency room visits that would impact patient safety or data interpretation:

• Due to poor glucose control in the 6 months prior to screening or
• Any bariatric surgical procedures for weight loss.
• Significant change of body weight (>10%) in the 3 months before screening
• Proliferative retinopathy or maculopathy within the 6 months before screening or requiring acute treatment, or severe neuropathy